|
⚲
|
| Keyboard |
| Bleichroeder LP
✚
|
|
|---|---|
| CRD # | 304295 |
| SEC # | 801-117171 |
| CIK # | 0001781002 |
| AUM | 2,431.2 M (2026-03-16) |
| Employees | 7 (86% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 212-984-3815 |
| Address | 1345 Avenue of The Americas New York, NY 10105 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/16/2026) [Brochure] |
|---|
Item 5: Fees and Compensation Bleichroeder typically receives compensation from its Clients from the following sources: (a) fees based on a percentage of assets under management; and (b) fees or allocations based on a percentage of the performance of the Client accounts. Fees for Managed Account clients are negotiable. Bleichroeder is entitled to enter into side letter agreements with some Investors in the Funds varying the terms of their investment, including lower fee arrangements. Current and prospective clients should carefully review all fees charged by Bleichroeder. Different fees are charged to different Clients and Investors, and fees can be waived, rebated, or reduced for certain Clients and Investors. Management Fee: In consideration for its services to the Funds, Bleichroeder is generally entitled to a management fee measured as a percentage of average monthly value of each Investor’s capital account balance during the particular quarter (the “Management Fee”). Bleichroeder, at its sole discretion can offer to investors different classes of interest in the Funds with preferential terms. For more details regarding the Management Fee and different classes of interests in the Funds, please refer to the applicable Fund Governing Documents. Generally, the Management Fee is calculated and paid each calendar quarter in arrears. Bleichroeder or the General Partner, as applicable, can reduce or eliminate the Management Fee with respect to any Investor in its sole discretion. Bleichroeder and its affiliates may not be charged any Management Fees with respect to their interests in the Funds. Performance based Compensation: Subject to certain terms and limitations disclosed in the Governing Documents, Bleichroeder is entitled to receive performance-based compensation (the “Incentive Allocation”) with respect to the Funds in an amount equal to a percentage of the net capital appreciation attributable to each Investor’s capital account in the Fund (after taking into account expenses of the Fund, including any Management Fees). The Incentive Allocation is generally payable annually after year‐end or at the time the Investor withdraws from the Fund if before year‐end. The Incentive Allocation will be calculated on the basis of the aggregate balance in an Investor’s capital account, irrespective of how many or when capital contributions are made to such capital account by such Investor. An Incentive Allocation can also be subject to what is commonly known as a “high water mark.” That is, if a capital account underperforms during a calendar year, the net underperformance will be recorded and carried forward to future calendar years (such amount is referred to as the “Loss Carryforward”), and Bleichroeder will not receive the Incentive Allocation with respect to such capital account for future calendar years until the Loss Carryforward amount has been recovered (i.e., when the Loss Carryforward amount has been exceeded by the cumulative net outperformance in the calendar years following the Loss Carryforward), unless otherwise noted. Once the Loss Carryforward has been recovered, the Incentive Allocation shall generally be based on the excess net capital appreciation over the Loss Carryforward amount, rather than on all net capital appreciation. The “high water mark” procedure prevents Bleichroeder from receiving the Incentive Allocation for net capital appreciation that simply restores previous underperformance and is intended to ensure that the Incentive Allocation is based on the long-term performance of the Fund. In some instances, Clients may pay Bleichroeder a performance-based compensation in the form of a carried interest (“Carried Interest”). The Carried Interest is typically calculated based on a share of capital gains on or capital appreciation of the assets of each Fund, as negotiated and determined at the time such Fund is established and as set forth in its Governing Documents. The Carried Interest is generally not paid until all investors have received aggregate distributions equal to the sum of their capital contributions to the Fund and subject to a specified, annually compounded preferred return, if any and a related general partner catch-up provision. Managed Account Clients can also be subject to the Management Fee and performance-based compensation similar to those described above. The level of compensation can vary by Client, based on a Client’s investment objectives and limitations. Bleichroeder is generally entitled to deduct fees directly from the Client accounts. Except as provided herein or the constituent Governing Documents, Bleichroeder renders its services to the Clients at its own expense and is responsible for its overhead expenses including: office rent; utilities; furniture and fixtures; stationery; secretarial/internal administrative services; salaries and bonuses; entertainment expenses; employee insurance and payroll taxes. Other Expenses Charged to the Clients: Expenses described below are general in nature and not intended to be exhaustive. For more information regarding expenses associated with investing in a particular Fund investment or strategy, please refer to applicable Fund Governing Documents. Managed Account expenses vary by Client and are negotiated directly with each prospective client prior to commencement of advisory services and over time. As detailed in applicable Fund documentation, investors are generally subject to the following expenses associated with their investments in a Fund, in addition to the Management Fee and Incentive Allocation described above: the organizational and initial offering costs of the Fund, including legal, accounting, printing, marketing and comparable expenses. Each Investor bears a Fund’s pro rata share of operating expenses that include, but are not limited to: legal, compliance, auditing, accounting and other professional expenses, administration ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/16/2026) [Brochure] |
|---|
Item 7: Types of Clients As mentioned in Item 4, Bleichroeder provides investment advisory services to Managed Accounts and Funds. Interests in the Funds is offered only to sophisticated and qualified investors, including but not limited to: high-net-worth individuals, family offices and institutions. The minimum investment in the Funds is generally $100,000, although Bleichroeder can elect to accept a lesser amount in its sole discretion. As of the date of this Brochure, Bleichroeder does not have a set minimum to open a Managed Account. |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| SPDR Gold Trust | 204.4 | ||
| Roman DBDR Tech Acquisition Corp | 67.9 | ||
| Resolute Holdings Management Inc | 51.0 | ||
| Linde PLC | 33.9 | ||
| Mdxhealth Sa | 17.0 | ||
| Intellicheck Mobilisa Inc | 14.5 | ||
| Information Systems Associates Inc | 11.2 | ||
| Identive Group Inc | 10.7 | ||
| Blackstone Group LP | 10.4 | ||
| Precision Biosciences Inc | 9.1 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Bleichroeder Private Investments LLC Series 2 | 2025-03-28 | 11.9 M | |
| HF | Coherence Equity Partners LP | 2022-04-28 | 26.8 M | |
| PE | Bleichroeder Private Investments LLC | 2021-03-23 | ||
| Other | Bleichroeder UV LLC | 2021-03-23 | 356.3 M | |
| HF | 21 April Fund Ltd | [2014-03-31] | 179.6 M | 441.0 M |
| Filed 2012-03-12 (D/A) · Exemption 506, 3(c), 3(c)(1) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | 21 April Fund LP | [2012-03-30] | 161.3 M | 194.4 M |
| Filed 2023-03-30 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Biotechnology Master Fund Ltd | [2012-03-30] | 68.2 M | 4.1 M |
| Filed 2018-03-13 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 33 | 0.4 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 5 | 1.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 6 | 0.9 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 13 | 0.1 |
| (n) Other | 0 | 0.0 |
| Total | 57 | 2.4 |
| By Discretionary | ||
| Discretionary | 57 | 2.4 |
| Non-Discretionary | 0 | 0.0 |
| Total | 57 | 2.4 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.5 | |
| United States Persons | 1.9 | |
| Total | 57 | 2.4 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Martin Byrne | Director | 130 | 21 | |
| Steven Schaefer | Director | 21 | 5 | |
| First Eagle Investment Management LLC | Executive Officer | 20 | 4 | |
| Tim Tabor | Executive Officer | 15 | 4 | |
| Curtis Lowell Jr | Director | 10 | 4 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001781002] | |
| 3 | [0001781002] | |
| 4 | [0001781002] | |
| SC 13D | [0001781002] | |
| SC 13G | [0001781002] |
| Firm Profile (Form ADV) | |
|---|---|
| Clients | 10 (18 non-US) |
| Serves | Institutional, Retail |
| Fund Types | Hedge Fund, Private Equity |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
First Eagle Real Estate Debt Fund FERLX
Shares of Beneficial Interest, Class I Shares
|
2025-08-06 | Buy | 633,161.85 | $25.27 | 16,000,000 |
|
First Eagle Real Estate Debt Fund FERLX
Shares of Beneficial Interest, Class I Shares
|
2025-04-30 | Buy | 354,645.18 | $25.16 | 8,922,873 |
|
Scientific Industries Inc SCND
Common Stock
|
2025-04-18 | Buy | 250,000 | $1.00 | 250,000 |
|
Scientific Industries Inc SCND
Warrants to Purchase Common Stock · derivative
|
2025-04-18 | Buy | 250,000 | ||
|
Liqtech International Inc LIQT
Warrants to Purchase Common Stock · derivative
|
2025-03-26 | Other | 531,250 | ||
|
Liqtech International Inc LIQT
Warrants to Purchase Common Stock · derivative
|
2025-03-26 | Other | 531,250 | ||
|
DUOS Technologies Group Inc DUOT
Warrants to Purchase Common Stock · derivative
|
2024-09-19 | Option exercise | 300,000 | $0.00 | |
|
DUOS Technologies Group Inc DUOT
Warrants to Purchase Common Stock · derivative
|
2024-09-19 | Option exercise | 44,644 | $0.00 | |
|
DUOS Technologies Group Inc DUOT
Series E Convertible Preferred Stock · derivative
|
2024-09-19 | Other | 12,500 | $1,000.00 | 12,500,000 |
|
DUOS Technologies Group Inc DUOT
Series E Convertible Preferred Stock · derivative
|
2024-09-19 | Other | 12,500 | $1,000.00 | 12,500,000 |
|
DUOS Technologies Group Inc DUOT
Common Stock
|
2024-09-19 | Option exercise | 344,644 | $2.61 | 899,521 |
|
DUOS Technologies Group Inc DUOT
Warrants to Purchase Common Stock · derivative
|
2024-09-19 | Other | 300,000 | ||
|
DUOS Technologies Group Inc DUOT
Warrants to Purchase Common Stock · derivative
|
2024-09-19 | Other | 44,644 | ||
|
DUOS Technologies Group Inc DUOT
Warrants to Purchase Common Stock · derivative
|
2024-09-19 | Other | 300,000 | ||
|
DUOS Technologies Group Inc DUOT
Warrants to Purchase Common Stock · derivative
|
2024-09-19 | Other | 44,644 | ||
|
DUOS Technologies Group Inc DUOT
Warrants to Purchase Common Stock · derivative
|
2024-07-22 | Buy | 300,000 | ||
|
GPGI Inc cmpo
Common Stock
|
2024-05-09 | Buy | 800,000 | $6.50 | 5,200,000 |
|
DUOS Technologies Group Inc DUOT
Series E Convertible Preferred Stock · derivative
|
2024-03-22 | Buy | 1,000 | $1,000.00 | 1,000,000 |
|
Scientific Industries Inc SCND
Warrants to Purchase Common Stock · derivative
|
2023-12-13 | Other | 278,947 | ||
|
Scientific Industries Inc SCND
Warrants to Purchase Common Stock · derivative
|
2023-12-13 | Buy | 960,000 | ||
| showing 20 of 124 most recent transactions | |||||
| Related Firms | State | AUM |
|---|---|---|
|
Bleichroeder LP
✚
|
NY | 2,431.2 M |
|
Goldiron GP LLC
✚
|
NY | 60.2 M |
| Comparable Firms | State | AUM |
|---|---|---|
|
Brevet Capital Management LLC
✚
|
NY | 2,566.0 M |
|
Basso Capital Management LP
✚
|
CT | 2,558.1 M |
|
Chickasaw Capital Management LLC
✚
|
TN | 2,545.9 M |
|
North Star Investment Management Corporation
✚
|
IL | 2,502.4 M |
|
Spruceview Capital Partners LLC
✚
|
CO | 2,342.5 M |
|
Baldwin Wealth Partners LLC
✚
|
MA | 2,334.7 M |
|
Cramer Rosenthal McGlynn LLC
✚
|
CT | 2,266.4 M |
|
Clear Haven Capital Management LLC
✚
|
NY | 2,183.6 M |
|
Kintegral Advisory LLC
✚
|
NY | 2,138.8 M |
|
NFC Investments LLC
✚
|
TN | 2,137.5 M |